(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2007 (18.01.2007)

PCT

(10) International Publication Number
WO 2007/007119 A1

(51) International Patent Classification:
C07D 239/42 (2006.01) *C07D 239/30* (2006.01)
C07D 239/36 (2006.01)

(21) International Application Number:
PCT/GB2006/003543

(22) International Filing Date: 3 July 2006 (03.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0514078.5 8 July 2005 (08.07.2005) GB

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BUTTERS, Michael** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB). **COX, David, Kenneth** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB). **CRABB, Jeffrey, Norman** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB). **LENGER, Steven, Robert** [US/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB). **MURRAY, Paul, Michael** [IE/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB). **SNAPE, Evan, William** [GB/GB]; AstraZeneca, Avlon Works, Severn Road, Bristol BS10 7ZE (GB).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES



(V)

(57) Abstract: A process for the manufacture of a compound of formula (V), useful for making rosuvastatin, by a stereoselective aldol reaction is described. Novel intermediates and processes to make them are also described.

WO 2007/007119 A1

CHEMICAL PROCESS

This invention concerns a novel chemical process, and more particularly it concerns a novel chemical process for the manufacture of rosuvastatin and its pharmaceutically acceptable salts, especially rosuvastatin calcium, as well novel intermediates used in said process and processes for the manufacture of the novel intermediates.

Rosuvastatin and its pharmaceutically acceptable salts are HMG CoA reductase inhibitors and have use in the treatment of, inter alia, hypercholesterolemia and mixed dyslipidemia. Rosuvastatin calcium (Formula (A)) is marketed under the trademark CRESTOR™. European Patent Application, Publication No. (EPA) 0521471 discloses (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid (rosuvastatin) and its sodium salt and calcium salt (rosuvastatin calcium, illustrated below) and a process for their preparation.



(A)

Rosuvastatin and its pharmaceutically acceptable salts are obtained therein by condensation of methyl (3R)-3-[(*tert*-butyldimethylsilyl)oxy]-5-oxo-6-triphenylphosphoranylidene hexanoate with 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldehyde, followed by deprotection of the 3-hydroxy group, asymmetric reduction of the 5-oxo group and hydrolysis.

Other processes for the preparation of rosuvastatin and its pharmaceutically acceptable salts are described in WO 00/49014 and WO 04/52867. The compound and its pharmaceutically acceptable salts are obtained in WO 00/49104 by reaction of diphenyl [4-(4-fluoropheny)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-ylmethyl]

phosphine oxide with tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl}acetate in the presence of a base, followed by removal of protecting groups. WO 04/52867 discloses the condensation of 1-cyano-(2S)-2-[(tert-butyldimethylsilyl)oxy-4-oxo-5-triphenylphosphoranylidene pentane with 4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methanesulfonylamino)-5-pyrimidinecarboxaldehyde, followed by deprotection, asymmetric reduction of the 4-oxo group and hydrolysis.

However there is a continuing need to identify alternative processes for the manufacture of rosuvastatin and its pharmaceutically acceptable salts. Such processes may, for example, when compared to previously known processes, be more convenient to use, be more suitable for large scale manufacture, give the product in a better yield, reduce the number of steps involved, use intermediates which are more easily isolated, require less complex purification techniques, use less expensive reagents and/or be more environmentally friendly.

WO 03/064382 describes a process for manufacture of statin compounds such as, inter alia, pitavastatin and rosuvastatin, based on an asymmetric aldol reaction using a chiral titanium catalyst. WO 03/42180 describes a similar process for the synthesis of pitavastatin.

We have now discovered a particularly useful process for preparing rosuvastatin and its pharmaceutically acceptable salts, using a variant of the process in WO 03/064382 which we have found to be particularly beneficial in terms of yield and/or enantiomeric excess of the product.

According to a first aspect of the invention, there is provided a process for the manufacture of a compound of formula (I)



(I)

or a pharmaceutically acceptable salt thereof, comprising

a) reaction of a compound of formula (II)



(II)

wherein each R^1 is independently selected from (1-6C)alkyl, and R is selected from (1-6C)alkyl, (3-6C)cycloalkyl or aryl(1-6C)alkyl;

with a compound of formula (III)



(III)

in the presence of a titanium (IV) catalyst of formula (IV)



(IV)

(wherein each R^2 is independently selected from (1-6C)alkyl and the binaphthyl moiety is in the S-configuration), an alkali metal halide salt and an amine, in an inert solvent, to give a compound of formula (V);



(V)

b) reduction of the keto-group in the compound of formula (V) to give a compound of formula (VI);



(VI)

and

c) removal of the R group to give the compound of formula (I) or a salt thereof; optionally followed by formation of a pharmaceutically-acceptable salt.

Suitable conditions for the reactions are described below.

Step a)

The use of the alkali metal halide and the amine are believed to be essential for obtaining good yield and enantiomeric excess for this reaction with the compound of formula (III).

The molar ratio of the aldehyde of formula (III) and a compound of formula (II) initially present in the reaction mixtures is conveniently between 1:1 and 1:6, such as from 1:1 to 1:4, conveniently between 1:1.5 and 1:3, such as 1:2.

The molar ratio of the titanium (IV) catalyst of formula (IV) to the aldehyde of formula (III) initially present in the reaction mixture is conveniently between 0.01:1 and 0.15:1, such as between 0.01:1 and 0.05:1.

The molar ratio of the alkali metal halide to the aldehyde of formula (III) initially present in the reaction mixtures is conveniently between 0.03:1 to 1:1, particularly between 0.1:1 and 0.4:1. The exact quantity of alkali metal halide to be used will be understood by the skilled person to depend on which amine is used and/or the amount of the titanium catalyst used, and/or the concentration of the reaction solution. The quantities given above are particularly suitable when the alkali metal halide is lithium chloride.

The molar ratio of the amine to the aldehyde of formula (III) initially present in the reaction mixture is conveniently between 0.015:1 and 2:1, particularly between 0.5:1 and

1.5:1, preferably about 1:1. The exact quantity of amine to be used will be understood by the skilled person to depend on which amine is used and/or the amount of the titanium catalyst used and/or the amount of metal salt used and/or the concentration of the reaction solution. The quantities given above are particularly suitable when the amine is TMEDA.

The reaction may be carried out in a polar aprotic solvent, such as tetrahydrofuran, diethylether or dimethoxyethane, preferably tetrahydrofuran. A combination of solvents may also be used.

The reaction may be carried out at a temperature from about 0°C to about 70°C, such as from about 10°C to about 60°C and preferably from about 15°C to about 30°C.

A preferred alkali metal halide is lithium chloride.

A preferred amine is N,N,N,N-tetramethylethylenediamine (TMEDA). Alternative amines include DABCO (1,4-diazabicyclo[2.2.2]octane), morpholine and N,N-dimethylpiperazine. In one aspect preferred amines are bidentate.

Examples of (1-6C)alkyl include methyl, ethyl, propyl, isopropyl and tert-butyl. Examples of (3-6C)cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of aryl(1-6C)alkyl include benzyl.

Suitably each R^1 group is methyl. Suitably R is selected from (1-6C)alkyl, particularly R is ethyl.

A compound of formula (II) may be prepared according to the procedures described in WO03/064382 and WO03/42180, and in J. Am. Chem. Soc., 1993, p. 830.

A compound of formula (IV) may be prepared according to the procedures described in WO03/064382 and WO03/42180.

A compound of formula (III) may be made by the following procedure, as illustrated in the accompanying Examples and as shown in Scheme 1 below.



Scheme 1

It will be understood that the present invention encompasses the use of the compound of formula (III) made by any suitable method and is not restricted to that shown in the above scheme. However the route shown in Scheme 1 is believed to be novel and is provided as a further independent aspect of the invention.

In a further aspect of the invention, there is provided a process for the manufacture of a compound of formula (III) comprising:



(III)

i) forming a compound of formula (XI) from a compound of formula (X); and



(X)



(XI)

ii) converting the compound of formula (X) to the compound of formula (III).

Suitably the compound of formula (XI) may be made by reacting the compound of formula (X) with acrylonitrile in the presence of a transition metal catalyst, such as a palladium catalyst, such as $Pd[P(tBu)_3]_2$ [pre-prepared or generated in situ from, for example bis(dibenzylideneacetone)palladium(0) ($Pd(dba)_2$) or tris(dibenzylideneacetone)dipalladium(0) ($Pd_2(dba)_3$) and $^tBu_3PH{\cdot}BF_4$]. A phase transfer catalyst, such as tetrabutylammonium bromide may be used.

Suitably, conversion of the compound of formula (XI) to the compound of formula (III) may be carried out by reduction using DIBAL (diisobutylaluminium hydride). Further suitable reducing agents include the following and complexes thereof: Raney nickel (with a source of H_2), tin(II)chloride, lithium triethylborohydride, potassium 9-*sec*-amyl-9-boratabicyclo[3.3.1]nonane, diisopropylaluminum hydride, lithium triethoxyaluminum hydride, lithium diethoxyaluminum hydride, sodium diethylaluminum hydride, lithium aluminium hydride, lithium tris(dialkylamino)aluminium hydrides, and trialkylsilanes in the presence of appropriate Lewis acids.

More suitably, conversion of the compound of formula (XI) to the compound of formula (III) may be carried out by reduction using DIBAL, for example in toluene at <0°C.

Further suitable conditions for these reactions may be found in the accompanying examples, or are well known in the art.

The compound of formula (III), namely *trans*-N-(4-(4-fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-enyl)pyrimidin-2-yl)-N-methylmethanesulfonamide is believed to be novel and is provided as a further aspect of the invention.

The compound of formula (VII), namely 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol is believed to be novel and is provided as a further aspect of the invention.

The compound of formula (VIII), namely 5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol is believed to be novel and is provided as a further aspect of the invention.

The compound of formula (IX), namely 5-bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine is believed to be novel and is provided as a further aspect of the invention.

The compound of formula (X), namely N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide is believed to be novel and is provided as a further aspect of the invention.

The compound of formula (XI), namely *trans*-N-(5-(2-cyanovinyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide is believed to be novel and is provided as a further aspect of the invention.

An alternative process for making the compound of formula (III) is by reaction of a compound of formula (X) with an appropriate vinylic boron species.

Therefore according to a further aspect of the invention, there is provided a process for forming a compound of formula (III) (as hereinbefore defined) comprising
A) reaction of a compound of formula (X) (as hereinbefore defined) with a vinyl boronate of formula (XII)



(XII)

wherein BY_x is selected from $B(OH)_2$, $B(OH)_3^-$, $B(OH)_2F^-$, BX_3^- (wherein X=halogen), $B(OR^5)_2$, $B(OR^5)_2F^-$, $B(OR^5)_2(OH)^-$, $B(OR^6)(OR^7)$, $B(OR^6)(OR^7)(OH)^-$, $B(OR^6)(OR^7)F^-$, $BR^5{}_2$, $BR^5{}_2OH^-$ and BR^5F^-;

R^5 is selected from (1-6C)alkyl, (3-6C)cycloalkyl and aryl(1-6C)alkyl;

R^6 and R^7 together form a two or three carbon alkylene bridge between the two oxygens to which they are attached, optionally substituted by 1, 2, 3 or 4 methyl or phenyl groups;

or R^6 and R^7 together form a phenyl ring;

and R^3 is a protecting group;

followed by deprotection to give a compound of formula (XIII):



(XIII)

and

B) oxidation of the compound of formula (XIII) to give the compound of formula (III).

Suitable values for R^3 include well known hydroxy protecting groups, and include for example $Si(R^4)_3$ (wherein each R^4 is independently selected from (1-6C)alkyl), tetrahydropyranyl, benzyl, *p*-methoxybenzyl, methoxymethyl (MOM) and benzyloxymethyl (BOM). Preferably OR^3 is not an ester group.

In one aspect, R^3 is $Si(R^4)_3$ (for example trimethylsilyl, or tertbutyldimethylsilyl). In another aspect R^3 is tetrahydropyranyl.

Suitably BY_x is $B(OR^6)(OR^7)$.

Examples of $B(OR^6)(OR^7)$ include:








In one aspect, $B(OR^6)(OR^7)$ is:



Suitably the reaction of (XII) with (X) may be carried out in the presence of a palladium catalyst such as (1,1'-bis(di-*tert*-butylphosphino)ferrocene)palladium(II) chloride. The reaction may be carried out in acetonitrile and water, in the presence of a base, such as potassium carbonate. Alternatively, the reaction may be carried out in the presence of fluoride, see for example *J. Org. Chem.*, **1994**, *59*, 6095-6097.

It will be appreciated that for some values of R^3 (for example when R^3 is $Si(R^4)_3$, the silyl group may be removed in situ during step A). When R^3 is tetrahydropyranyl, a separate step may be required to deprotect the intermediate allyl ether to give the alcohol (XIII); this may be carried out for example by hydrolysis using aqueous hydrochloric acid. This deprotection step may be carried out without isolation of the intermediate allyl ether, as illustrated in the accompanying examples. When R^3 is *p*-methoxybenzyl group, it may be removed under oxidative conditions which simultaneously oxidise the hydroxy group to give an aldehyde of formula (III).

Suitably the oxidation of (XIII) to give (III) (Step B) may be carried out using manganese dioxide, for example in toluene. Other oxidation conditions well known in the art may also be used, for example variations on the Swern oxidation, such as would be achieved using chlorine and dimethylsulfide.

Further suitable conditions for these reactions may be found in the accompanying examples.

The compound of formula (XIII), namely *trans*-N-(4-(4-fluorophenyl)-5-(3-hydroxyprop-1-enyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide is believed to be novel and forms a further aspect of the invention.

Step b)

Reduction of the keto group in the compound of formula (V) may be carried out in the presence of a di(loweralkyl)methoxyborane, such as diethylmethoxyborane or dibutylmethoxyborane. Suitably diethylmethoxyborane is used. The reaction is generally carried out in a polar solvent, such as tetrahydrofuran or an alcohol such as methanol or ethanol, or a mixture of such solvents, for example a mixture of tetrahydrofuran and methanol.

The reducing agent is suitably a hydride reagent such as sodium or lithium borohydride, particularly sodium borohydride.

The reaction may be carried out at reduced temperatures, such as about –20°C to about -100°C, particularly about –50°C to about -80°C.

Similar chiral reductions are described in EP0521471.

Step c)

The R group in the compound of formula (VI) may be removed by hydrolysis under conditions well known in the art, to form the compound of formula (I), or a salt thereof. Such salts may be pharmaceutically-acceptable salts, or may be transformed into pharmaceutically-acceptable salts. For example, R may be hydrolysed by treatment with aqueous sodium hydroxide to form the sodium salt of (I).

A suitable pharmaceutically acceptable salt includes, for example, an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example, calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example with methylamine, ethylamine, dimethylamine, trimethylamine, morpholine, diethanolamine, tris(2-hydroxyethyl)amine and tris(hydroxymethyl)methylamine.

The compound of formula (I) is marketed as its calcium salt as described hereinbefore. The calcium salt may be formed directly as a product of the reaction to remove the R group (for example by treating the compound of formula (VI) with aqueous calcium hydroxide, see patent application US 2003/0114685) or by treating an alternative salt of the compound of formula (I), such as the sodium salt, with an aqueous solution of a suitable calcium source. Suitable calcium sources include calcium chloride and calcium acetate. This is illustrated in Scheme 2:



Scheme 2

Suitable conditions for transformation of the sodium salt to the calcium salt are described in EP0521471. It will be appreciated that the resulting calcium salt may be retreated if desired in order to obtain different particle size, or different physical form (such as amorphous vs crystalline) by processes known in the art (see for example International Patent Applications WO00/42024 and WO2005/023779).

In a further aspect of the invention, there is provided a process for the manfacture of a compound of formula (VI)



(VI)

comprising:

a) reaction of a compound of formula (II)



(II)

wherein each R^1 is independently selected from (1-6C)alkyl, and R is selected from (1-6C)alkyl, (3-6C)cycloalkyl or aryl(1-6C)alkyl;

with a compound of formula (III)



(III)

in the presence of a titanium (IV) catalyst of formula (IV)



(IV)

(wherein R^2 is (1-6C)alkyl and the binaphthyl moiety is in the S-configuration), an alkali metal halide salt and an amine, in an inert solvent, to give a compound of formula (V);



(V)

and

b) reduction of the keto-group in the compound of formula (V) to give a compound of formula (VI).

Suitable conditions for steps a) and b) are as hereinbefore described.

In a further aspect of the invention there is provided a process for the manufacture of a compound of formula (V)



(V)

comprising

reaction of a compound of formula (II)



(II)

wherein each R^1 is independently selected from (1-6C)alkyl, and R is selected from (1-6C)alkyl, (3-6C)cycloalkyl or aryl(1-6C)alkyl;

with a compound of formula (III)



(III)

in the presence of a titanium (IV) catalyst of formula (IV)



(IV)

(wherein R^2 is (1-6C)alkyl and the binaphthyl moiety is in the S-configuration), an alkali metal halide salt and an amine, in an inert solvent.

Suitable conditions for this reaction are as described hereinbefore for process a).

In a further aspect of the invention there is provided a process for the manufacture of a compound of formula (VI) comprising

a) forming a compound of formula (V) as hereinbefore described; and further comprising

b) reduction of the keto-group in the compound of formula (V) to give a compound of formula (VI).



(VI)

According to a further aspect of the invention, there is provided a process for forming a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising

a) forming a compound of formula (V) and b) forming a compound of formula (VI) as hereinbefore described; and further comprising

c) removal of the R group to give the compound of formula (I) or a salt thereof; optionally followed by formation of a pharmaceutically-acceptable salt.



(I)

Under certain conditions, as illustrated in the accompanying examples, it is possible to carry out the reduction of compound (V) to compound (VI) and the subsequent conversion to compound (I) or a salt thereof, without isolation of the intermediate compound (VI). Telescoping two reactions into one step in this way would be expected to be efficient and cost effective, provided product quality is not compromised.

According to a further aspect of the invention, there is provided a process for formation of a compound of formula (I) or a salt thereof, wherein steps b) and c) are carried out without isolation of the intermediate compound of formula (VI).

Examples

In the following non-limiting Examples, unless otherwise stated:

(i) evaporations were carried out by rotary evaporation in *vacuo* and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;

(ii) operations were carried out at room temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;

(iii) yields are given for illustration only and are not necessarily the maximum attainable;

(iv) the structures of the end-products of the Formula (I) were confirmed by nuclear (generally proton) magnetic resonance (NMR); proton magnetic resonance chemical shift values were measured on the delta scale (relative to tetramethylsilane) and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;

(v) intermediates were not necessarily fully characterised and purity was assessed by thin layer chromatography (TLC), melting point (Mp), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

(vi) Purification by chromatography generally refers to flash column chromatography, on silica unless otherwise stated. Column chromatography was generally carried out using prepacked silica cartridges (from 4g up to 400g) such as Biotage (Biotage UK Ltd, Hertford, Herts, UK), eluted using a pump and fraction collector system.

(vii) High Resolution Mass spectra (HRMS) data was generated using a Micromass LCT time of flight mass spectrometer.

(viii) melting point data were generally measured using Differential Scanning Calorimetry (DSC) using a Perkin Elmer Pyris 1. Values quoted are onset temperature.

The invention will be illustrated by the following examples, in which the following abbreviations are used:

DIBAL	di-isobutyl aluminium hydride
DCM	dichloromethane
EtOAc	ethylacetate
$CDCl_3$	deuterochloroform
DMF	dimethylformamide
MTBE	methyl tert-butyl ether

Example 1: (3*R*,5*S*)-*trans*-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid, calcium salt



Under a nitrogen atmosphere, (*S*)-*trans*-ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-hydroxy-3-oxohept-6-enoate (200 mg, 0.39 mmol) and methanol (0.67 mL) were dissolved in 5 mL tetrahydrofuran and cooled to –70°C. To this solution was added diethylmethoxyborane (1 M in tetrahydrofuran, 430 μL, 0.43 mmol) dropwise via syrine over 25 minutes. The resulting pale yellow solution was stirred 30 minutes at –78°C, then sodium borohydride (16.3 mg, 0.43 mmol) was added. The mixture was stirred for two hours at –78°, then the reaction was quenched with acetic acid (86 mg, 1.44 mmol) and allowed to warm to room temperature. To this was added 2 mL of 1M aqueous NaOH, and the resulting solution was stirred for 90 minutes. This was then diluted with 5 mL water and 5 mL toluene, stirred 30 minutes, separated, and aqueous concentrated *in vacuo* to give a pale oil. The oil was dissolved in 5 mL water, heated to 40°C, then aqueous calcium chloride (0.93 M, 300 μL, 0.28 mmol) was added dropwise via syringe. The resulting slurry was cooled to room temperature over 60 minutes, then the solids were collected via filtration with a 1 mL water wash. The collected solids were dried overnight under vacuum to yield (3*R*,5*S*)-*trans*-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid, calcium salt (122.6 g, 62% yield) as a white crystalline solid. Physical data were identical to existing standard and its published description.

(3*R*,5*S*)-*trans*-ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate



Under a nitrogen atmosphere, (*S*)-*trans*-ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-hydroxy-3-oxohept-6-enoate (506 mg, 1.00 mmol) and methanol (1.7 mL) were dissolved in 10 mL tetrahydrofuran and cooled to –76°C. To this solution was added diethylmethoxyborane (1.0 M in tetrahydrofuran, 1.15 mL, 1.15 mmol) dropwise via syrine over 30 minutes. The resulting pale yellow solution was stirred 30 minutes at –75°C, then sodium borohydride (43.5 mg, 1.15 mmol) was added. The reaction was stirred for two hours at –65°C, then the reaction was quenched with acetic acid (224 µL, 3.75 mmol) and allowed to warm to room temperature. It was diluted with 100 mL of methyl *tert*-butyl ether and 20 mL water, stirred vigorously for 10 minutes, then separated. The upper organic phase was washed with 20 mL water, 20 mL saturated aqueous $NaHCO_3$ solution, and then with 20 mL water, then concentrated *in vacuo* to give a pale oil, which was purified by Biotage chromatography (50:50 EtOAc/hexane) to yield the title product (182 mg, 36% yield) as a white solid. ^1H NMR (400MHz) ($CDCl_3$) δ: 1.27 (6H, d), 1.28 (3H, t), 2.45 (1H, s), 2.47 (1H, d), 3.37 (1H, m), 3.52 (3H, s), 3.57 (3H, s), 3.58 (1H, br. s), 3.74 (1H, br. s.), 4.19 (2H, q), 4.22 (1H, m), 4.46 (1H, m), 5.46 (1H, dd), 6.64 (1H, dd), 7.09 (2H, dd), 7.65 (2H, dd). Mp: 92-94°C. HRMS calculated for $C_{24}H_{32}FN_3O_6S$ 509.1996, found 509.1999.

(*S*)-*trans*-Ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-5-hydroxy-3-oxohept-6-enoate



Under a nitrogen atmosphere, *trans*-N-(4-(4-fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-enyl)pyrimidin-2-yl)-N-methylmethanesulfonamide (1.00 g, 2.65 mmol), (*S*)-(-)-1,1'-bi-(2-naphthyloxy)(diisopropoxy)titanium (41.8 mg, 0.093 mmol), and lithium chloride (40.2 mg, 0.94 mmol) were dissolved in tetrahydrofuran (15 mL) at room temperature. The solution was stirred for 10 minutes, then N,N,N'N'-tetramethylethylenediamine (397 μL, 2.51 mmol) was added via syringe, causing the solution to change from red to orange. To this solution was added 1,3-bis(trimethylsiloxy)-1-ethoxybuta-1,3-diene (1.45 g, 5.30 mmol) via syringe pump over 1 hour. The reaction mixture was stirred overnight at room temperature, then quenched at 0°C with 20% aqueous trifluoracetic acid (2.5 mL) and allowed to warm to room temperature over 1 hour. The mixture was cooled to 0°C, then 25% aqueous phosphoric acid (4 mL) was added and reaction was allowed to warm to room temperature. It was stirred for 1 hour, then diluted with methyl *tert*-butyl ether (50 mL). The mixture was separated, and the aqueous layer was extracted with methyl *tert*-butyl ether (2 x 50 mL). The combined organic fractions were washed with water (2 x 100 mL), dried ($MgSO_4$), and concentrated *in vacuo* to give a light yellow oil. Purification by chromatography (Biotage cartridge, 40:60 EtOAc/hexane) gave the title compound (1.221 g, 91% yield) as a pale oil in 99.3% enantiomeric excess.

^{1}H NMR (400MHz; $CDCl_3$) δ: 1.26 (6H, d), 1.28 (3H, t), 2.65 (1H, d), 2.66 (1H, s), 2.89 (1H, br. s), 3.34 (1H, m), 3.44 (2H, s), 3.51 (3H, s), 3.57 (3H, s), 4.21 (2H, q), 4.65 (1H, m), 5.45 (1H, dd), 6.67 (1H, dd), 7.11 (2H, dd), 7.63 (2H, dd).

HRMS calculated for $C_{24}H_{30}FN_3O_6S$ 507.1839, found 507.1870.

(*S*)-(-)-1,1'-bi-(2-naphthyloxy)(diisopropoxy)titanium



Under a nitrogen atmosphere, (*S*)-(−)-1,1'-bi(2-naphthol) (500 mg, 1.74 mmol), titanium tetraisopropoxide (500 µL, 1.69 mmol) and powdered 4Å molecular sieves (500 mg) were suspended in dichloromethane (25 mL) and stirred for one hour at room temperature. The solids were filtered off, and the filtrate concentrated *in vacuo* to provide (*S*)-(-)-1,1'-bi-(2-naphthyloxy)(diisopropoxy)titanium (980 mg, 126% yield) as a dark red powder which was used in subsequent reactions without further purification.

4-(4-Fluorophenyl)-6-isopropylpyrimidin-2-ol



The reactor used for this experiment was thoroughly dried by carrying out a toluene distillation prior to use. Fresh toluene (100 mL) and potassium tert-butoxide (7.50 g, 64.8 mmol) were charged to the vessel and stirred to form a slurry. The mixture was cooled to -9°C and 3-methyl-2-butanone (3.63 g, 41.7 mmol) added. The mixture was warmed to -5°C and stirred for 30mins. Ethyl-4-fluorobenzoate (6.25 g, 36.8 mmol) was dissolved in toluene (4 mL) and added via a syringe followed by a small toluene (1ml) line wash. The mixture was stirred for 10 minutes at 0°C, warmed to 10°C, and then stirred at this temperature overnight. The mobile slurry was warmed to 25°C and acetic acid (4.4 mL) added, followed by water (37.5 mL). The mixture was stirred thoroughly for 5 minutes and then allowed to stand. The lower phase was run off and discarded. A 5% sodium bicarbonate solution (16 mL) was charged to the upper phase, stirred for 5 minutes and

then allowed to stand. The lower aqueous layer was run off and the upper organic phase washed twice with water (5 mL).

The remaining toluene solution was dried by azeotropic distillation (refluxing with Dean-Stark trap in place) and the solution cooled to 60°C. Urea (5.1 g, 84.9 mmol) and isopropanol (20 mL) were charged and stirred vigorously during the addition of hydrochloric acid (5 to 6 M in isopropanol, 32.3 mL, 183mmol). The solution was heated to 80°C and stirred for 48.5 hours before charging more hydrochloric acid in isopropanol (2 mL, 11 mmol). After a total of 112 hours at 80°C, the mixture was cooled to 60°C and water (50 mL) added. After stirring for 15 minutes, the mixture was allowed to stand and the lower aqueous phase run off and retained. The aqueous phase was stirred and sodium hydrogen carbonate (6.9 g) added portion wise until pH=7. The product crystallised from solution and was then cooled to 20°C. The solid was filtered off and washed twice with water (20 mL) and dried in a vacuum oven at 50°C overnight. 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (4.92 g) was isolated as a white powder in 56% overall yield; ^{1}H NMR (400MHz; $CDCl_3$) δ: 1.41 (6H, d), 3.08 (1H, m), 6.69 (1H, s), 7.17 (2H, dd), 8.14 (2H, dd), 13.57 (1H, br. s). Mp: 215-217°C. HRMS calculated for $C_{13}H_{13}N_2OF$ 232.1012, found 232.0963; used in subsequent reaction without further purification.

5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol



4-(4-Fluorophenyl)-6-isopropylpyrimidin-2-ol (8.00 g, 34.1 mmol) was charged to a reactor followed by DMF (100 mL). The suspension was stirred, cooled to -3°C and N-bromosuccinimide (6.25 g, 34.8 mmol) added. The reaction mixture was warmed to 20°C and stirred overnight. Water (100 mL) was charged to the reaction mixture and the crystalline mixture stirred for 1 hour before filtering off. The isolated solid was washed twice with water (25 mL) and the solid dried in a vacuum oven at 50°C. 5-Bromo-4-(4-

fluorophenyl)-6-isopropylpyrimidin-2-ol (10.45 g, 97% yield) was obtained as a white solid;

^{1}H NMR (400MHz; $CDCl_3$) δ: 1.39 (6H, d), 3.57 (1H, m), 7.16 (2H, dd), 7.66 (2H, dd). Mp: Decomposes at 199°C. HRMS calculated for $C_{13}H_{12}N_2OFBr$ 310.0117, found 310.0116; used in subsequent reaction without further purification.

5-Bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine



Phosphoryl chloride (5.00 mL, 53.8 mmol) was added to 5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol (5.027 g, 15.28 mmol) and the reaction mixture was heated to an internal temperature of 90° C. The mixture was then stirred for 150 minutes at this temperature, then allowed to cool to 25°C. The reaction mixture was quenched by dropwise addition (with 30 mL of EtOAc rinses) into a stirred mixture of ice (60 g), water (40 mL), and sodium bicarbonate (10 g). After completion of the addition, sodium bicarbonate (13 g) added to assure neutrality. The mixture was then extracted with ethyl acetate (4 x 70 mL). The organic phases were combined and dried with anhydrous magnesium sulphate. The solution was filtered through a pad of diatomaceous earth, and concentrated *in vacuo* to yield the title compound (4.98 g, 99% yield).

^{1}H NMR (400MHz; $CDCl_3$) δ: 1.34 (6H, d), 3.64 (1H, m), 7.17 (2H, dd), 7.73 (2H, dd). Mp: 99-101°C. HRMS calculated for $C_{13}H_{11}N_2FClBr$ 327.9778, found 327.9752; used in subsequent reaction without further purification.

N-(5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide



Sodium hydride (1.20 g, 30.0 mmol, 60% suspension in mineral oil) was washed with hexane (2 x 10 mL), and DMF (50 mL) was then added, followed by 5-bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine (4.944 g, 15.0 mmol). The resulting suspension was cooled to –7°C and N-methylmethanesulfonamide (2.585 g, 22.5 mmol) was added, washed in with DMF (10 mL). The mixture was stirred for 17.5 hours, then diluted with ethyl acetate (80 mL), toluene (100 mL), and water (120 mL). The organic phase was separated, and the aqueous phase was extracted with a mixture of ethyl acetate (20 mL) and toluene (30 mL). The organic phases were combined, washed with water (2 x 40 mL) and then brine (20 mL), and dried over anhydrous magnesium sulphate. The solution was concentrated *in vacuo* (with 2 x 20 mL hexane azeotropes) to yield the title compound (5.50 g, 91% yield).

^{1}H NMR (400MHz; $CDCl_3$) δ: 1.32 (6H, d), 3.49 (3H, s), 3.55 (3H, s), 3.63 (1H, m), 7.16 (2H, dd), 7.77 (2H, dd). Mp: 122-125°C. HRMS calculated for $C_{13}H_{17}N_3O_2FSBr$ 401.0209, found 401.0225; used in subsequent reaction without further purification.

***trans*-N-(5-(2-Cyanovinyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide**



N-(5-Bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (20.0 g, 49.72 mmol), tetra-N-butylammonium bromide (3.24 g, 10 mmol), and bis(tri-tert-butylphosphine)palladium(0) (1.48 g, 2.89 mmol) were charged to a 500ml round bottom flask. The flask was flushed for five minutes with nitrogen, then toluene (200 mL), dicyclohexylmethylamine (31.6 mL, 147 mmol), acrylonitrile (3.60 mL, 54.67 mmol) were added via syringe and the reaction was stirred. The resulting amber solution was heated in an oil bath at 50°C for 7 hours, over which time a beige precipitate began to form. The reaction was allowed to cool to room temperature, was diluted with *iso*-hexane (200 mL), then cooled further to –8°C. The precipitate was collected by filtration and washed with *iso*-hexane (4 x 100 mL) to give a crude product (31g wet) consisting of roughly 85% *trans* isomer. To the crude product was added methanol (130 mL) and the resulting suspension was stirred at room temperature for 30 minutes, then cooled to –8°C. The white crystalline solids were collected by filtration and dried overnight in a vacuum oven to give the title compound (13.1 g, 70% yield) as a white crystalline solid.

^{1}H NMR (400MHz; $CDCl_3$) δ: 1.32 (6H, d), 3.29 (1H, m), 3.51 (3H, s), 3.58 (3H, s), 5.31 (1H, d), 7.18 (2H, dd), 7.49 (1H, d), 7.58 (2H, dd); Mp: 134.5°C.

HRMS calculated for $C_{18}H_{19}FN_4O_2S$ 374.1213, found 374.1210.

***trans*-N-(4-(4-Fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-enyl)pyrimidin-2-yl)-N-methylmethanesulfonamide**



trans-N-(5-(2-Cyanovinyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (12.83 g, 34.27 mmol) was dissolved in toluene (750 mL) and cooled to –9°C. To this solution was added DIBAL (20% solution in toluene, 34 mL, 41.1 mmol) over 45 minutes via syringe pump, maintaining an internal temperature of below –6°C. After the addition was complete, the reaction was allowed to warm slowly to room temperature overnight and then quenched with methanol (3 mL) followed by 1 M HCl

(41.1 mL). The resulting suspension was filtered, and lower aqueous layer of the filtrate was separated. The organic layer of the filtrate was treated with 1 M HCl (100 mL), and the resulting suspension was filtered. The layers were separated and the organic layer was washed with brine (125 mL), saturated aqueous $NaHCO_3$ (125 mL), and water (125 mL), then treated with $MgSO_4$ and Novit SX 1G carbon, filtered, and conentrated *in vacuo* to give 12 g yellow oil. This was purified by chromatography (Biotage cartridge, 100% DCM) to yield the title compound (9.7 g, 76% yield) as a pale yellow amorphous solid. ^1H NMR (400MHz; $CDCl_3$) δ: 1.32 (6H, d), 3.39 (1H, m), 3.53 (3H, s), 3.60 (3H, s), 6.22 (1H, dd), 7.15 (2H, dd), 7.52 (1H, d), 7.59 (2H, dd), 9.61 (1H, d); Mp: 86.5°C. HRMS calculated for $C_{18}H_{20}FN_3O_3S$ 377.1209, found 377.1196.

<u>*trans*-N-(4-(4-Fluorophenyl)-5-(3-hydroxyprop-1-enyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide</u>



To a room temperature solution of (1,1'-bis(di-*tert*-butylphosphino)ferrocene)palladium(II) chloride (162 mg, 0.249 mmol) and potassium carbonate (10.3 g, 74.6 mmol) in acetonitrile (40 mL) and water (40 mL) was added *trans*-4,4,5,5-tetramethyl-2-(3-(tetrahydro-2H-pyran-2-yloxy)prop-1-enyl)-1,3,2-dioxaborolane (see Synthesis, 2004, p. 1814-1820; 11.9 g (70% strength), 31.1 mmol) as a solution in acetonitrile (35 mL) with a water rinse (12.5 mL). The mixture was stirred for 5 minutes, then N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (10.0 g, 24.9 mmol) was added as a white solid followed by water (12.5 mL). The reaction was heated to reflux (77°C internal temperature) for five hours, then allowed to cool to room temperature. It was diluted with MTBE (150 mL) and water (150 mL), separated, and the organic layer was washed twice with water (50 mL) then concentrated *in vacuo*, providing 16 g of a brown oil. This material was dissolved in 150 mL acetonitrile at room

temperature, and 10 M aqueous hydrochloric acid (3.0 mL, 30 mmol) was added. The resulting mixture was stirred for 45 minutes at room temperature, then quenched with sodium bicarbonate (2.52 g, 30 mmol). The mixture was diluted with toluene (150 mL) and water (150 mL), separated, and organic layer was washed twice with water (40 mL). The organic layer was dried over sodium sulfate, concentrated *in vacuo*, and purified by chromatography (1:1 iso-hexane/EtOAc, 450 g silica gel) to yield the title compound (8.29 g, 72% yield) as a light yellow oil. ^{1}H NMR (400MHz) ($CDCl_3$) δ: 1.27 (6H, d), 3.38 (1H, m), 3.51 (3H, s), 3.57 (3H, s), 4.20 (2H, d), 5.65 (1H, ddd), 6.58 (1H, ddd), 7.09 (2H, dd), 7.59 (2H, dd). HRMS calculated for $C_{18}H_{22}FN_3O_3S$ 379.1366, found 379.1392.

<u>*trans*-N-(4-(4-Fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-enyl)pyrimidin-2-yl)-N-methylmethanesulfonamide</u>



To a room temperature solution of *trans*-N-(4-(4-fluorophenyl)-5-(3-hydroxyprop-1-enyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (1.81 g (95% strength), 4.53 mmol) in 25 mL toluene was added manganese dioxide (10 g (85% strength), 97.77 mmol). The resulting suspension was stirred for 18 hours, then filtered through a pad of Celite with a toluene rinse. The solvents were removed from the filtrate *in vacuo* to give the title compound (1.33 g, 75% yield) as a yellow oil that rapidly became a crystalline solid. ^{1}H NMR (400MHz) ($CDCl_3$) δ: 1.32 (6H, d), 3.39 (1H, m), 3.53 (3H, s), 3.60 (3H, s), 6.22 (1H, dd), 7.15 (2H, dd), 7.52 (1H, d), 7.59 (2H, dd), 9.61 (1H, d). Mp: 86.5°C. HRMS calculated for $C_{18}H_{20}FN_3O_3S$ 377.1209, found 377.1196.

Claims

1. A process for the manufacture of a compound of formula (V)



(V)

comprising

a) reaction of a compound of formula (II)



(II)

wherein each R^1 is independently selected from (1-6C)alkyl, and R is selected from (1-6C)alkyl, (3-6C)cycloalkyl or aryl(1-6C)alkyl;

with a compound of formula (III)



(III)

in the presence of a titanium (IV) catalyst of formula (IV)



(IV)

(wherein each R^2 is independently selected from (1-6C)alkyl and the binaphthyl moiety is in the S-configuration), an alkali metal halide salt and an amine, in an inert solvent.

2. A process for the manufacture of a compound of formula (VI) comprising

a) forming a compound of formula (V) according to claim 1; and further comprising

b) reduction of the keto-group in the compound of formula (V) to give a compound of formula (VI).



(VI)

3. A process for forming a compound of formula (I) or a pharmaceutically acceptable salt thereof, comprising

a) forming a compound of formula (V) and b) forming a compound of formula (VI) according to claim 2; and further comprising

c) removal of the R group to give the compound of formula (I) or a salt thereof;

optionally followed by formation of a pharmaceutically-acceptable salt.



(I)

4. A process according to claim 3 wherein steps b) and c) are carried out without isolation of the intermediate compound of formula (VI).

5. A process according to any one of claims 1 to 4 wherein the alkali metal halide is lithium chloride.

6. A process according to any one of claims 1 to 5 wherein the amine is N,N,N,N-tetramethylethylenediamine (TMEDA).

7. A process according to any one of claims 1 to 5 wherein each R^1 is methyl.

8. A process according to any one of the preceding claims wherein R is (1-6C)alkyl.

9. A process according to any one of the preceding claims wherein the compound of formula (I) is isolated as its calcium salt.

10. A process for the manufacture of a compound of formula (III) as defined in claim 1 comprising:



(III)

i) forming a compound of formula (XI) from a compound of formula (X); and



(X)



(XI)

ii) converting the compound of formula (X) to the compound of formula (III).

11. A process according to claim 10 wherein step i) is carried out by reaction of compound (X) with acrylonitrile in the presence of $Pd[P(tBu)_3]_2$.

12. A process according to claim 10 or claim 11 wherein step ii) is carried out by reaction with DIBAL.

13. A process for forming a compound of formula (III) (as defined in claim 1) comprising

A) reaction of a compound of formula (X) (as defined in claim 8) with a vinyl boronate of formula (XII)



(XII)

wherein BY_x is selected from $B(OH)_2$, $B(OH)_3^-$, $B(OH)_2F^-$, BX_3^- (wherein X=halogen), $B(OR^5)_2$, $B(OR^5)_2F^-$, $B(OR^5)_2(OH)^-$, $B(OR^6)(OR^7)$, $B(OR^6)(OR^7)(OH)^-$, $B(OR^6)(OR^7)F^-$, BR^5_2, $BR^5_2OH^-$ and BR^5F^-;

R^5 is selected from (1-6C)alkyl, (3-6C)cycloalkyl or aryl(1-6C)alkyl;

R^6 and R^7 together form a two or three carbon alkylene bridge between the two oxygens to which they are attached, optionally substituted by 1, 2, 3 or 4 methyl or phenyl groups;

or R^6 and R^7 together form a phenyl ring;

and R^3 is a protecting group;

followed by deprotection to give a compound of formula (XIII):



(XIII)

and

B) oxidation of the compound of formula (XIII) to give the compound of formula (III).

14. A process as claimed in Claim 13 wherein R^3 is tetrahydropyranyl.

15. A process as claimed in Claim 13 or Claim 14 wherein the BY_x is $B(OR^6)(OR^7)$.

16. The compound *trans*-N-(4-(4-fluorophenyl)-6-isopropyl-5-(3-oxoprop-1-enyl)pyrimidin-2-yl)-N-methylmethanesulfonamide.

17. The compound 4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol.

18. The compound 5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-ol.

19. The compound 5-bromo-2-chloro-4-(4-fluorophenyl)-6-isopropylpyrimidine.

20. The compound N-(5-bromo-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide.

21. The compound *trans*-N-(5-(2-cyanovinyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide.

22. The compound *trans*-N-(4-(4-fluorophenyl)-5-(3-hydroxyprop-1-enyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/003543

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D239/42 C07D239/36 C07D239/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/064382 A2 (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; CHEN GUANG-PEI [US]; KAPA) 7 August 2003 (2003-08-07) cited in the application abstract page 5 page 8 claims	1,16
P,X	CN 1 763 015 A (SICHUAN IND I OF ANTIBIOTICS C [CN]) 26 April 2006 (2006-04-26) the whole document	1,10,16

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
21 November 2006	29/11/2006

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Stix-Malaun, Elke

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/003543

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 2006/100689 A (UNICHEM LAB LTD [IN]; DESHPANDE PANDURANG BALWANT [IN]; RAMAKRISHNAN A) 28 September 2006 (2006-09-28) abstract page 8 claims 4,5	13,16
E	WO 2006/076845 A (ANHUI QINGYUN PHARMACEUTICAL A [CN]; HUANG QINGYUN [CN]) 27 July 2006 (2006-07-27) abstract claims 5,6	10,16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2006/003543

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03064382 A2	07-08-2003	BR 0307236 A	07-12-2004
		CA 2472340 A1	07-08-2003
		CN 1625550 A	08-06-2005
		CN 1660818 A	31-08-2005
		EP 1472227 A2	03-11-2004
		JP 2005516064 T	02-06-2005
		MX PA04007308 A	29-10-2004
CN 1763015 A	26-04-2006	NONE	
WO 2006100689 A	28-09-2006	NONE	
WO 2006076845 A	27-07-2006	CN 1807418 A	26-07-2006